The USPTO has ruled there is “no interference in fact” in the closely-watched dispute over CRISPR patents between the University of California and the Broad Institute, reports MIT Technology Review.

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.